0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover312.68%IV-88.68%PremiumDec 20, 2024Expiry Date0.94Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6843Delta0.4532Gamma1.01Leverage Ratio-0.0066Theta-0.0008Rho-0.69Eff Leverage0.0009Vega
CytomX Stock Discussion
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target t...
No comment yet